Use of procalcitonin in clinical oncology: a literature review.
Use of procalcitonin in clinical oncology: a literature review.
复制标题
DOI：
--
复制
发表时间：
2016-04
期刊：
影响因子：
--
通讯作者：
A. Sbrana;M. Torchio;G. Comolli;A. Antonuzzo;M. Danova
中科院分区：
文献类型：
--
作者：
A. Sbrana;M. Torchio;G. Comolli;A. Antonuzzo;M. Danova
使用降钙素原（PCT）作为癌症患者感染发作的早期标志物仍然存在争议。我们对 1990 年 1 月至 2015 年 12 月期间发表的同行评审文章进行了 MEDLINE 检索，最终分析了 15 篇文章。 PCT 似乎对癌症患者的感染事件具有良好的诊断价值，如果我们考虑血流感染和败血症等重大事件，其准确性似乎更高。这种蛋白质的系列评估似乎在诊断阶段更准确，并且有助于预测结果和对抗菌治疗的反应。另一方面，一些问题尚未解决，例如使用经过验证的测定方法、标准截止值的定义以及不同患者环境之间的异质性（例如早期癌症与晚期癌症，或血液肿瘤与实体瘤）。然而，可以相信，PCT 在日常临床实践中的使用，最好与其他临床或实验室测试相结合，可能有助于发现和检测癌症患者的早期感染并发症。
The use of procalcitonin (PCT) as an early marker of infectious episodes in cancer patients is still controversial. We performed a MEDLINE search of peer-reviewed articles published between January 1990 and December 2015, and finally we analysed 15 articles. PCT seems to have a good diagnostic value of infectious episodes in cancer patients and its accuracy seems greater if we consider major events, such as bloodstream infections and sepsis. Serial evaluations of this protein seem to be more accurate in the diagnostic phase and useful to predict outcome and response to antibacterial treatment. On the other hand, some issues have yet to be solved, such as the use of a validated method of determination, the definition of a standard cut-off, and the heterogeneity among different settings of patients (e.g. early versus advanced-stage cancer, or haematological versus solid tumours). However, it is credible to think that PCT use in everyday clinical practice, preferably in combination with other clinical or laboratory tests, might be of help in finding and detecting early infectious complications in cancer patients.